Shinnihonseiyaku Co., Ltd. (JP:4931)
:4931
Top Page
Shinnihonseiyaku Co., Ltd.
(4931)
Select Model
Select Model
Rating:64Neutral
Price Target:
¥2,127.00
▼(-4.70% Downside)
Action:ReiteratedDate:12/18/25
The overall score of 64 for JP:4931 is primarily driven by a solid financial performance (score: 73), with a strong balance sheet and decent cash flow, though tempered by declining revenue. Bearish technical indicators (score: 45) reflect a downward price trend, weighing on the score, while a reasonable valuation (score: 68) provides moderate support. Financial stability remains the key strength, but growth challenges and weak momentum are notable risks.
Positive Factors
Strong Balance Sheet
A strong balance sheet with minimal leverage provides financial stability and flexibility, allowing the company to invest in growth opportunities without significant financial risk.
Negative Factors
Declining Revenue Growth
Declining revenue growth poses a challenge for future expansion and market share, potentially impacting the company's ability to invest in new products and technologies.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Balance Sheet
A strong balance sheet with minimal leverage provides financial stability and flexibility, allowing the company to invest in growth opportunities without significant financial risk.
Read all positive factors
Shinnihonseiyaku Co., Ltd. (4931) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥44.56B
Dividend Yield2.53%
Average Volume (3M)55.11K
Price to Earnings (P/E)10.1
Beta (1Y)0.44
Revenue Growth2.74%
EPS Growth-7.19%
CountryJP
Employees316
SectorConsumer Cyclical
Sector Strength84
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)50.21
Shares Outstanding21,855,200
10 Day Avg. Volume51,180
30 Day Avg. Volume55,106
Financial Highlights & Ratios
PEG Ratio-2.68
Price to Book (P/B)2.13
Price to Sales (P/S)1.18
P/FCF Ratio10.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)161.7
Revenue Forecast (FY)¥43.45B
Shinnihonseiyaku Co., Ltd. Business Overview & Revenue Model
Company Description
Shinnihonseiyaku Co., Ltd. (4931) is a Japanese company primarily engaged in the manufacturing and sale of pharmaceutical products, including prescription drugs, over-the-counter medicines, and health supplements. The company operates in the healt...
How the Company Makes Money
Shinnihonseiyaku generates revenue primarily through the sale of its pharmaceutical products, which include both prescription medications and OTC drugs. The company benefits from a well-established distribution network that enables it to reach hea...
Shinnihonseiyaku Co., Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
85
Very Positive
Cash Flow
70
Positive
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 41.14B | 40.04B | 37.65B | 36.11B | 33.90B |
| Gross Profit | 32.58B | 31.53B | 29.98B | 29.07B | 28.08B |
| EBITDA | 5.15B | 4.49B | 4.19B | 3.95B | 3.85B |
| Net Income | 2.55B | 2.79B | 2.39B | 2.36B | 2.32B |
Balance Sheet | |||||
| Total Assets | 28.44B | 27.28B | 25.50B | 23.86B | 23.24B |
| Cash, Cash Equivalents and Short-Term Investments | 18.12B | 16.34B | 15.52B | 14.35B | 13.65B |
| Total Debt | 76.00M | 253.00M | 446.00M | 1.84B | 2.24B |
| Total Liabilities | 5.63B | 5.48B | 5.84B | 5.94B | 7.06B |
| Stockholders Equity | 22.81B | 21.79B | 19.66B | 17.92B | 16.18B |
Cash Flow | |||||
| Free Cash Flow | 4.63B | 1.93B | 3.37B | 2.25B | 1.97B |
| Operating Cash Flow | 4.69B | 2.10B | 3.47B | 2.29B | 2.07B |
| Investing Cash Flow | -1.79B | -382.00M | -208.00M | -496.00M | -1.36B |
| Financing Cash Flow | -2.10B | -902.00M | -2.10B | -1.09B | 672.00M |
Shinnihonseiyaku Co., Ltd. Technical Analysis
Positive
2232.00
Price Trends
2076.70
Positive
2061.74
Positive
2166.76
Negative
Market Momentum
7.23
Negative
57.74
Neutral
87.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4931, the sentiment is Positive. The current price of 2232 is above the 20-day moving average (MA) of 2068.80, above the 50-day MA of 2076.70, and above the 200-day MA of 2166.76, indicating a neutral trend. The MACD of 7.23 indicates Negative momentum. The RSI at 57.74 is Neutral, neither overbought nor oversold. The STOCH value of 87.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4931.
Shinnihonseiyaku Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ¥44.56B | 10.10 | ― | 2.53% | 2.74% | -7.19% | |
63 Neutral | ¥43.96B | 239.59 | ― | ― | ― | ― | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
60 Neutral | ¥511.03B | 22.79 | ― | 0.93% | 3.73% | 18.84% | |
57 Neutral | ¥36.54B | 10.10 | ― | 1.29% | 7.12% | 14.14% | |
48 Neutral | ¥6.14B | -12.09 | ― | 2.65% | 15.66% | 56.93% | |
47 Neutral | ¥9.18B | -6.49 | ― | ― | ― | ― |
* Consumer Cyclical Sector Average
JP:4931
Shinnihonseiyaku Co., Ltd.
2,082.00
-162.62
-7.24%
JP:2796
Pharmarise Holdings Corp.
523.00
60.52
13.09%
JP:3349
COSMOS Pharmaceutical Corporation
6,420.00
-1,643.88
-20.39%
JP:7679
Yakuodo Holdings Co., Ltd.
1,851.00
73.20
4.12%
JP:190A
Chordia Therapeutics Inc.
128.00
-122.00
-48.80%
JP:219A
Heartseed, Inc.
1,923.00
-434.00
-18.41%
Shinnihonseiyaku Co., Ltd. Corporate Events
Shinnihonseiyaku Announces Treasury Share Disposal for Employee Stock Compensation
Dec 17, 2025
Shinnihonseiyaku Co., Ltd. has announced the disposal of treasury shares as part of a stock compensation plan for employees, aimed at aligning employee incentives with corporate goals. This move is expected to enhance corporate value and promote v...
Shinnihonseiyaku Announces Treasury Shares Disposal for Director Compensation
Dec 17, 2025
Shinnihonseiyaku Co., Ltd. announced the disposal of treasury shares as stock compensation for its board directors, excluding outside directors and audit committee members. This move is part of their strategy to incentivize directors by aligning t...
Shinnihonseiyaku Evaluates and Plans to Enhance Board Effectiveness
Nov 13, 2025
Shinnihonseiyaku Co., Ltd. has conducted an evaluation of its Board of Directors’ effectiveness for the fiscal year ended September 2025, in line with the Tokyo Stock Exchange’s Corporate Governance Code. The evaluation revealed that w...
Shinnihonseiyaku Announces Director Elections Ahead of Shareholders Meeting
Nov 13, 2025
Shinnihonseiyaku Co., Ltd. has announced the election of candidates for various director positions, including Directors of the Board, Audit Supervisory Committee Members, and a Substitute Director. These elections are subject to approval at the u...
Shinnihonseiyaku Proposes Dividend of Surplus for 2025
Nov 13, 2025
Shinnihonseiyaku Co., Ltd. announced a proposal for a dividend of surplus, with a record date of September 30, 2025, to be submitted at the upcoming Annual General Meeting. The proposed year-end dividend per share is 52.00 yen, reflecting the comp...
Shinnihonseiyaku Co., Ltd. Reports Strong Growth and Sets Ambitious Targets
Nov 11, 2025
Shinnihonseiyaku Co., Ltd. reported a 9.4% year-over-year increase in net sales and a 4.6% rise in operating profit for the fiscal year ending September 2025, driven by the strong performance of its Fun and Health segment. The company plans to con...
Shinnihonseiyaku Reports Fiscal Year 2025 Financial Results and Optimistic Outlook
Nov 11, 2025
Shinnihonseiyaku Co., Ltd. reported its consolidated financial results for the fiscal year ended September 30, 2025, showing a modest increase in net sales by 2.7% to 41,140 million yen. Despite an increase in operating and ordinary profits, the p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.